Flying With Crohn's Disease Medication

Injectable Crohn's medication travels in your cabin bag, never the hold, and the number you actually need before you pack is your own product's room-temperature allowance, because it is not the flat "14 days" the internet repeats. Reading the US labels for seven drugs used in Crohn's and ulcerative colitis, the allowance ranges from 30 days down to none at all.

That single fact reorders the whole trip. If your biologic can sit at 25 degrees C for a month, a two-week holiday needs a carton and a bit of shade, not a cold chain. If it cannot, you need a cool bag that survives every leg of the journey plus every re-screening, and you need to know what happens at hour 42.

This guide is about the medication and the logistics around it: temperature, packaging, documentation, security, customs, infusion timing, vaccines and insurance. For the toilet-access and travellers' diarrhoea side of travel, our guide to travelling with IBS-D covers that ground in detail and most of it transfers.

The short answer, in the order the decisions actually happen

Work through it in this sequence, because each answer changes the next one.

1. What am I taking, and what does its own carton say about temperature? Not what a forum says about biologics in general.
2. How many hours is the door-to-fridge journey, including layovers and the drive at the far end? This is the number that decides whether you need cooling at all.
3. Will I re-clear security mid-journey? If yes, your cool packs are exposed to a second screening, and that is where people lose them.
4. Is a dose due while I am away, and where will it be stored between arrival and injection?
5. Does anything I carry contain a controlled drug, and does my destination restrict it?
6. Do I have a written summary and insurance that names my condition?

Everything below is detail on those six. If you only do two things, put the medication in your cabin bag and read your own leaflet's storage section before you buy a cool bag you may not need.

Your product's room-temperature window is not 14 days

The most repeated claim in travel threads is that biologics are fine out of the fridge for 14 days, with "some only 7". That is adalimumab's number being generalised. Here is what the US prescribing information says for products used in Crohn's disease and ulcerative colitis, read directly from the labels on DailyMed.

Four things follow from that table, and they are the practical heart of this article.

The spread is more than four-fold, and one product has no window at all. Somebody on ustekinumab and somebody on risankizumab are having completely different conversations, even though both would read the same generic travel advice page. If you take risankizumab, do not assume a warm-weather week in a carton is fine because a Humira thread said so.

The allowance is usually a single, one-way period. The certolizumab and ustekinumab labels say plainly that once the syringe has been at room temperature you do not put it back in the fridge. So a pen that spent a day warm on the outbound leg has started its clock, and refrigerating it at the hotel does not restart it. Both labels also tell you to write the date it came out on the carton, which is the instruction people skip and then cannot reconstruct three weeks later.

"Room temperature" has a ceiling, and it is not the temperature of a parked car or a beach bag. Adalimumab, certolizumab, golimumab and the vedolizumab pen cap at 25 degrees C; ustekinumab and mirikizumab at 30 degrees C. A summer holiday can exceed both. Protection from light, in the original carton, is part of the same instruction and is genuinely part of the condition.

Every one of them says do not freeze. That is the sentence that decides checked versus cabin.

Why the hold is the risk, and why the risk is cold rather than heat

The advice "never check your biologic" circulates widely without a mechanism attached. Here is the mechanism, and here is the limit of what is actually known.

Freezing and thawing a therapeutic antibody can make it clump. In bench work on frozen and thawed tumour necrosis factor inhibitors, researchers put etanercept, adalimumab and certolizumab pegol samples, still in their original primary and secondary packaging, through either 32 freeze-thaw cycles (minus 10 degrees C for 120 minutes alternating with 5 degrees C for 60 minutes) or a continuous minus 20 degrees C for 96 hours, chosen to mimic storage conditions previously recorded in patients' homes. Ten of 21 stressed samples (47.6%) showed more particles in the submicron and micron size range than unstressed controls. Two of the five analytical methods, size-exclusion chromatography and ultraviolet spectroscopy, showed no difference at all (Vlieland 2018).

Two honest notes about that paper. First, its own conclusion sentence begins "TNF-alpha inhibitors are relatively resistant to freezing temperatures", and then immediately reports that almost half the stressed samples formed particles. We could not reconcile the adjective with the number from the abstract, and both readings are in the same paragraph, so we are printing both rather than choosing the more quotable one. Second, and more importantly, the study measured particles, not whether the drug still worked in a person. Nobody has run the trial where half the participants inject a frozen-and-thawed pen. So the correct claim is "freezing changes the product in ways the manufacturers designed the label to prevent", not "a frozen pen will not work". The study was funded by University Medical Center Utrecht.

The mechanism behind it is well described. In hydrogen-exchange work on a different antibody entirely, bevacizumab, a cancer drug rather than an IBD one, aggregation increased with the number of freeze-thaw cycles and, interestingly, decreased at higher protein concentration. Freeze-thaw produced native-like aggregates while heat produced non-native ones, meaning the two stresses damage a protein by different routes (Zhang 2012).

Heat, within limits, appears to be the more forgiving direction. A stability study of the adalimumab biosimilar CT-P17 alongside reference adalimumab and two other biosimilars held them at either 5 or 25 degrees C with 60% relative humidity for 28 days and reported quality maintained across the products over that period, with slight differences in charge variants, oxidation, purity and subvisible particle counts (Shin 2021). Disclose the obvious: that study was funded by Celltrion, the manufacturer of CT-P17, and co-authored by its employees. And note what it does and does not license. It does not extend anyone's label from 14 days to 28. Stability data in a laboratory and a regulator-approved storage instruction are different objects, and the instruction is the one written on your carton.

One gap worth naming, because every other page glosses it: we could not find published temperature measurements for passenger aircraft baggage holds, or any study on whether security screening affects biologic medicines. So the case for the cabin does not rest on a measured hold temperature. It rests on the labels' do-not-freeze instruction, the evidence that freezing is the error people make, and the ordinary fact that checked bags get delayed, misrouted and opened. That is enough. It just is not the same as a number, and you should be suspicious of any page that gives you one without a source.

What the security rules actually say, and what everyone gets wrong

Here is where the received wisdom and the published rules diverge, in both directions.

United States. The TSA position is that you may bring medically necessary liquids, medications and creams in excess of 3.4 ounces or 100 millilitres in your carry-on bag, in reasonable quantities for your trip, but you must declare them to officers at the checkpoint for inspection, and they should be removed from your bag and screened separately (TSA, travelling with medication). On labelling, the wording is "it is recommended that medication be clearly labeled to facilitate the screening process". Neither that page nor the liquid medications page lists a doctor's letter or a prescription as a requirement (TSA, liquid medications). There is one caveat worth knowing: oversized medically necessary liquids that alarm during screening can be refused at the checkpoint.

United Kingdom. You are allowed essential medicines of more than 100 ml in hand luggage. You need proof that the medication is prescribed to you, for example a letter from your doctor or a copy of your prescription, only if it is both in liquid form and in a container larger than 100 ml. You do not need proof for tablets, or for liquid in a container of 100 ml or smaller (GOV.UK).

Read that carefully against what you are carrying. A prefilled biologic pen holds well under one millilitre. Strictly, then, the UK documentation rule does not bite for a cool bag of pens, because no single container is over 100 ml. Hypodermic syringes are listed as allowed in both hand and hold luggage.

And then the detail nobody writes about, which is on the same GOV.UK table: cooling gel packs are allowed in hand luggage, while ice packs are listed as "contact the airport". Both are permitted in hold luggage. If you are flying from a UK airport with a cool bag, that distinction is the one that decides whether you make a phone call before you leave, and it is a distinction most travel guides collapse into "ice packs are fine".

This matches, uncomfortably, what people report. In a r/CrohnsDisease thread on international travel with biologics, one traveller described a long layover during which their packs went slushy, and being refused them at the second screening (thread). A pack that is no longer frozen solid looks, to a screening officer, like a bag of liquid.

Controlled drugs are a separate rulebook

If anything you carry contains a controlled drug, a codeine-based painkiller for example, the rules change and they are not airline rules, they are border rules. UK guidance is that you should ask your doctor or pharmacist whether your medicine contains a controlled drug, check the destination country's rules with its embassy before travelling, and prove the medicine is yours with a prescription or a letter from your doctor. Bringing such a medicine into the UK, the letter must include your name, your travel dates, a list of your medicines with quantities, doses and strengths, and the prescriber's signature, and you can bring at most three months' supply (GOV.UK).

The point is not that your painkiller is suspicious. It is that the evidence requirement here is real and specific, unlike the security-letter folklore, and that countries differ enough that "it is legal at home" is not a plan. Check the destination, not the departure airport.

Keeping it cold for 40 hours: where the plan breaks

The Reddit thread that set this article going describes the realistic hard case: a three-month trip, 13 weekly pens, a flight cancellation turning the itinerary into 42 hours door to door, the manufacturer's own travel cooler too small for the number of pens and not rated for that duration, and no obvious route to a consumer cold-chain courier (thread).

There is no trick that solves that. What the threads converge on is a set of trade-offs worth knowing before you improvise.

Manufacturer travel coolers exist and are usually free, and they are sized for a dose or two. Several people describe requesting one from the manufacturer or a specialist nurse (thread). For a two-week holiday with one injection due, that is the whole answer. For 11 pens across 42 hours, it is not.

Insulated bags sold for insulin are the same problem already solved. Diabetes is vastly more common than Crohn's, so the consumer market for a small medical cool bag was built for insulin, and multiple people in the threads point that out.

Splitting the supply is usually better than a bigger cooler. Carry the doses you will need for the first stretch, then arrange a cold shipment or a local supply for the rest. People in the thread describe asking a family member to ship a resupply, using a courier's healthcare service, or asking whether the manufacturer can arrange a local supply at the destination. All of those are questions for your specialist pharmacy or IBD team rather than the internet, because the answer depends on your country, your prescription and your funder.

Plan for the re-screening, not the flight. The failure point in these accounts is almost never the aircraft. It is a long layover where packs thaw, or a second checkpoint, or the car at the other end.

The galley fridge is a favour. One traveller describes asking cabin crew on a 14-plus hour flight to keep their pens in the fridge and the crew agreeing (thread). That is lovely and it works. It is also unmonitored, ungoverned by any airline commitment, and one distraction away from your medication landing in Seattle without you.

And the real hazard: over-engineering towards freezing. One detailed post describes wrapping syringes in plastic and foil, layering ice and gel packs in a vacuum flask, and measuring 4 degrees C after 35 hours. It ends with the right warning: biologics need to be kept above freezing. Packing ice directly against a pen for 35 hours is exactly the exposure the Vlieland freezing work was modelling. If you build your own, the thing to protect against is not only heat.

Planning a trip around an infusion or an injection date

Get your team to move the date. Do not move it yourself, and do not stretch an interval because the calendar is awkward.

The reason is specific rather than vague. In a cohort of 125 people with Crohn's disease receiving infliximab infusions, antibodies against infliximab were detected in 61%, and pre-infusion antibody concentrations of 8.0 micrograms per millilitre or more predicted a shorter duration of response, 35 days versus 71 days, and a higher risk of infusion reactions, relative risk 2.40 (95% CI 1.65 to 3.66). Concomitant immunosuppressive therapy predicted lower antibody titres (Baert 2003). That study is about immunogenicity rather than about travel, and it predates modern proactive drug monitoring, but it is the cleanest illustration of why the interval is not arbitrary.

Reassuringly, teams do not generally want you off treatment for a trip. In a survey of 305 IBD physicians across 23 countries, two-thirds said they would continue all IBD treatments and not cease any medications for travel. The same survey found specialists more willing to advise against travel to a tuberculosis-endemic area for someone on combined anti-TNF and azathioprine than for someone on vedolizumab and azathioprine (47% versus 17.6%, p less than 0.01), which tells you the conversation is drug-specific (Chan 2018).

Practical sequence, four to eight weeks out:

1. Tell your team the dates and ask whether an infusion or injection can be shifted, and in which direction they would rather move it.
2. Ask for a buffer supply, and for it to be dispensed early enough that you are not collecting a prescription the day before you fly.
3. Ask what they want you to do if symptoms escalate abroad, and get it in writing. "Contact us" is a plan; "see a doctor" is not.
4. Ask whether your destination has an IBD service they would point you to, and whether your biologic is available there under a different brand name.
5. Confirm where you will store the medication at the other end. A minibar fridge is not always a fridge.

The vaccine gate is the bit people leave too late

This is the single most time-sensitive item, and the one most often missed. Live vaccines are generally avoided while a person is on immunosuppressive therapy, and travel to some destinations involves exactly those vaccines. Yellow fever vaccine is live-attenuated and is generally contraindicated in immunosuppressed patients (Burkhard 2020). Reviews of travel advice for immunocompromised travellers make the same point, that in some instances live vaccines and prophylactic medications may be contraindicated (Patel 2015).

Awareness of that is poor. In a UK survey of 132 people with IBD attending an outpatient clinic, 48% of those on immunomodulator therapy were unaware of the need to avoid live vaccines, only 23% had sought pre-travel medical advice at all, and among IBD health professionals surveyed alongside them, 27% were not confident providing pre-travel advice, with vaccination advice named as an area of uncertainty by 54% (Greveson 2016). It is not only patients who are unsure.

For the broader vaccination picture, the American College of Gastroenterology's 2025 preventive care guideline update notes that more than 70% of people with IBD will at some time be on immune-modifying therapies that may increase infection risk, many of those infections being preventable by vaccination, and that achieving this needs coordination between the primary care provider, the gastroenterology team and other specialists (Farraye 2025).

Two honest boundaries on this section. First, we are not telling you which vaccines you can or cannot have: that is a decision for your IBD team and a travel medicine clinic, made from your specific drugs and destination, and it often depends on timing relative to starting or continuing treatment. Second, the Burkhard study is frequently misread. It looked at people who were vaccinated against yellow fever before immunosuppression began, and found that a median of 21.1 years later 88% of the immunosuppressed group were still seropositive versus 89% of controls. That is evidence that prior immunity persists. It is not evidence that the vaccine is safe to give during immunosuppression, and the population was people with autoimmune rheumatic disease or organ transplants, not IBD.

In practice the gate is real: in the largest described cohort of immunocompromised post-transplant travellers seen at 17 US pre-travel clinics, none of the 317 received MMR and exactly one received yellow fever vaccine (Rolfe 2026). Again, transplant recipients rather than IBD, but it shows how travel clinics handle live vaccines in immunosuppressed people.

The timing consequence: book the travel clinic appointment as soon as you book the trip, not the fortnight before. Non-live alternatives, destination re-planning and timing around treatment all take weeks.

Does flying itself trigger a Crohn's flare?

One study is behind almost every claim you will read on this, and it deserves a careful read rather than a headline.

Researchers compared people with IBD who had at least one flare during a 12-month observation period against a group in remission, using a questionnaire. Among 103 patients (43 with Crohn's disease, 60 with ulcerative colitis), 52 with flares were matched to 51 in remission. Those who had flared more often reported a flight and/or a journey to a region above 2,000 m above sea level within four weeks of the flare: 21 of 52 (40.4%) versus 8 of 51 (15.7%), p = 0.005 (Vavricka 2014).

What that can and cannot support:

• The exposures are pooled. "Flights and/or journeys above 2,000 m" is a single variable. A week at altitude and a three-hour flight are counted the same way, so the study cannot tell you that the flight was the part that mattered.
• It is retrospective and questionnaire-based. People who had a flare are being asked to recall the previous four weeks. Recall in that direction is not neutral.
• It is small. Roughly 50 people per arm, with a single comparison driving the finding.
• Funding is worth stating. The grant list includes the Swiss National Science Foundation and the Swiss IBD Cohort, and also Vifor Pharma Ltd.

The same group's later review sets out the hypothesis, that hypoxia can induce gastrointestinal inflammation, mostly from animal work and studies in healthy mountaineers, and states that they had begun a controlled study exposing IBD patients in stable remission and healthy controls to a simulated 4,000 m for three hours in a pressure chamber (Vavricka 2016). The abstract we read describes the study design and says first results were forthcoming; it does not report them, so we cannot tell you what they showed.

The reasonable conclusion is not "do not fly". It is that the association exists, is weak, cannot be attributed to the flight specifically, and is a reason to travel with your medication in hand and a plan for symptoms rather than a reason to stay home. If symptoms do escalate on a trip, our guide to telling whether you are in a Crohn's flare covers separating a flare from a gut infection, which is the more common question abroad.

Clots on long flights, and the number that gets over-quoted

You will see "people with IBD have three times the DVT risk" on IBD travel pages. That figure is real and it is worth understanding properly before you act on it.

It comes from the Canadian Association of Gastroenterology consensus statements on venous thromboembolism in IBD, which state that IBD patients have an approximately 3-fold higher risk of VTE compared with people without IBD, and that disease flares increase that risk further (Nguyen 2014). Worth disclosing at the point of citation: the grant record for that consensus lists AbbVie Canada.

Two pieces of context change how you should weigh it.

What the same consensus recommends is narrower than the headline. It recommends anticoagulant thromboprophylaxis for IBD patients hospitalised with flares without active bleeding, and suggests it during moderate-to-severe flares in outpatients who have a history of VTE provoked by a flare or an unprovoked VTE, but not otherwise. In other words, the consensus itself does not translate a three-fold relative risk into routine prophylaxis for outpatients, and certainly not into something you should initiate yourself before a flight.

The absolute numbers are small. A UK cohort matching 23,046 IBD patients to 106,795 people without IBD found an overall thromboembolic hazard ratio of 1.74 (95% CI 1.55 to 1.96). Among ambulant patients, meaning people up and about rather than in hospital, risk was raised during acute disease activity (HR 3.94, 2.79 to 5.57) and chronic activity (3.97, 2.90 to 5.45), but their absolute risk remained below 5 per 1,000 person-years. The big absolute risks were in hospital and after major surgery, 59.5 per 1,000 person-years with surgery, and remained elevated for six weeks after discharge (Chu 2018). That study was funded by Crohn's and Colitis UK.

Travel adds its own increment. A meta-analysis of 14 studies including 4,055 VTE cases found a pooled relative risk of 2.0 (95% CI 1.5 to 2.7) for travellers versus non-travellers, rising to 2.8 (2.2 to 3.7) when studies using referred control participants were excluded, with a dose-response of 18% higher risk per additional two hours of travel by any mode and 26% per two hours of air travel (p = 0.005). All available studies were from Western countries (Chandra 2009).

So the picture for a well person with quiescent Crohn's on a long-haul flight is a modest multiplication of a small baseline. The picture changes materially if you are in the middle of a flare, if you have recently had abdominal surgery, or if you have had a clot before, and in those situations the flight is a conversation to have with your team before you book, not a reason to buy compression socks and hope. General measures like moving around the cabin and staying hydrated are sensible and free. Starting or changing any anticoagulant or antiplatelet medicine is a prescriber's decision, not a packing decision.

Getting ill abroad, and the thing it is most likely to be

Travel illness in IBD is common enough to plan for and not so common as to dominate a trip. In a survey of 1,878 people with IBD across the UK, Australia, New Zealand and Israel, 7.7% sought medical advice or were hospitalised while overseas, and 43.8% had cancelled or changed plans because of their IBD. The most common barriers reported were worry about toilet facilities (76.3%), cleanliness and sanitation (50.9%) and availability of medical care (41.1%) (Aluzaite 2021). That survey was funded by the Leona M and Harry B Helmsley Charitable Trust.

The clinically important point is that new diarrhoea abroad is not automatically a flare. In 295 stool PCR tests taken during symptom exacerbations in 214 people with IBD, 12.9% were positive for Clostridioides difficile and 13.8% for one of 14 other pathogens, with E. coli species most common: an enteric infection was detected in 79 (26.8%) of symptomatic patients (Axelrad 2017). And it matters which it is. In a matched retrospective cohort of 137 people, enteric infection at flare was independently associated with a worse composite outcome at two years, steroid dependence, colectomy or a change or escalation of IBD therapy, with an adjusted odds ratio of 4.14 (95% CI 1.62 to 11.5). When the infections were separated, C. difficile and E. coli were independently associated with that outcome and other pathogens were not (Dimopoulos-Verma 2024).

Translated into travel terms: if diarrhoea starts abroad, it is worth getting a stool test rather than assuming, and it is worth telling your team while you are still away rather than on your return. Treating a gut infection as a flare and escalating immunosuppression is the mistake that sequence is designed to prevent.

On antidiarrhoeals, the travel medicine evidence is not about IBD. A systematic review of loperamide in travellers' diarrhoea concluded that, at the manufacturer's dosage recommendations, loperamide is a safe and effective option for mild to moderate symptoms, that taking it alone did not predispose travellers to acquiring multidrug-resistant bacteria, and that there was no proof antibiotics are significantly more effective than loperamide for mild or moderate travellers' diarrhoea (Laaveri 2016). That population is general travellers. In active colitis, antimotility drugs are a different question with different risks, and whether you should carry or use one is a decision for your IBD team before you go, not something to work out from a travel article. The same review's main thrust, that reaching for antibiotics is not obviously better, is also a reason not to pack a self-directed antibiotic course.

If you do end up eating around symptoms far from home, what to eat during a Crohn's flare is a more useful starting point than a generic travel-food list, and if nausea is the leading symptom for you, nausea after eating with Crohn's covers the mechanisms that airline meals and irregular timing tend to aggravate.

Strictures, obstruction and the seat you choose

This is where Crohn's stops sharing an article with everything else. If you have narrowing anywhere in your bowel, or a history of obstruction, or a stoma, flying changes the risk profile in ways that a general IBD travel page will not tell you.

Gas expands as cabin pressure falls, which is a nuisance for most people and a more meaningful problem if there is a fixed narrowing for that gas and its contents to get past. The cabin-pressure and gas mechanics are covered in our travelling with IBS-D guide. The Crohn's-specific overlay is texture and timing: many people with stricturing disease find the long, food-dense, low-movement structure of a flight the hardest part, and the food most likely to cause trouble is the food most likely to be handed to you in a tray. If you have a stoma, the food list that matters is in foods that cause ileostomy blockage, and the same list is worth glancing at before an airport meal even without one.

Practical points that come from the threads rather than trials: aisle seats near a toilet if you can choose them, asking the airline in advance rather than at the gate, and being honest with yourself about whether a 40-hour itinerary with two layovers is the trip you should be taking this month.

Insurance: the most commonly skipped step

Two independent surveys say the same thing: people with IBD travel under-insured. In the four-country survey, 32.6% did not get travel insurance that covered their IBD, and people who had not received travel advice, or who found obtaining insurance difficult, were significantly less likely to obtain it at all (p less than 0.001). People travelling for work were more likely both to be hospitalised or seek medical advice overseas and not to have insurance (Aluzaite 2021). In the UK clinic survey, only 40% of travellers had obtained travel insurance, and 61% of IBD health professionals said obtaining travel insurance was an area of uncertainty for them (Greveson 2016).

What to check, in order: that the policy covers your IBD as a declared pre-existing condition and not merely "unrelated" emergencies; that it covers the cost of your medication if it is lost, damaged or spoiled; that it covers repatriation; that it covers cancellation if you flare before you travel, which is the clause that matters most given how many people cancel plans; and whether the insurer needs a letter from your team. Declaring the condition can raise the premium. Not declaring it can void the policy, which is the more expensive mistake.

If work is the reason you are flying, keeping a job with Crohn's disease covers the disclosure and adjustment side of business travel that this article deliberately does not.

Jet lag, sleep and the honest state of that evidence

Long-haul travel wrecks sleep, and there is a reasonable-sounding argument that circadian disruption is bad for IBD. Be careful about how strong you let that argument get.

A review in the Journal of the Canadian Association of Gastroenterology sets out the position explicitly as a hypothesis: the authors write that they "posit" circadian disruption is a key factor associated with flare risk and disease progression, based on circadian regulation of barrier integrity, mucosal immunity and host-microbe interaction, and on observations of "social jet lag" in people with IBD. They also state that circadian-directed interventions have potential to mitigate the impact of disrupted rhythms (Post 2025). That is a hypothesis-generating review funded by US National Institutes of Health grants, not a trial showing that jet lag causes flares or that fixing your sleep prevents them.

So: protecting sleep on a long trip is sensible for the reasons sleep is always sensible, and because fatigue is the symptom that most reliably ruins a holiday. It is not a proven flare-prevention strategy, and nobody should sell it to you as one. If travel fatigue is the part you dread, Crohn's fatigue in remission explains why it persists when inflammation is controlled, and how to explain Crohn's fatigue to people is genuinely useful before a trip with people who have not seen you at your worst.

Alcohol on the plane deserves one line, because free drinks plus dehydration plus a long sit is a combination people regret. Can you drink alcohol with Crohn's disease covers what the evidence does and does not show.

A worked example: 42 hours, 13 weekly pens

Take the hard case from the thread and work it through. This is an illustration of the reasoning, not a recommendation for anyone's trip.

The facts. Weekly adalimumab. Three-month trip. 13 pens needed. 42 hours door to door with layovers. Label allowance: up to 25 degrees C for up to 14 days, protected from light, one period only.

Step 1: split the problem. Two pens cover the first two weeks and can legitimately travel at room temperature inside their allowance, provided the 42 hours are inside it, the temperature stays under 25 degrees C and the date they left the fridge is written on the carton. The other 11 are a storage problem, not a travel-day problem.

Step 2: do not try to keep 13 pens cold for 42 hours. That is the brief that has no good answer. Instead the question becomes: can the remaining 11 arrive later, or be dispensed locally? That is a conversation with the specialist pharmacy, the manufacturer's patient support service and the IBD team, and it has to start weeks out.

Step 3: if they must travel with you, cold-chain them properly and keep them with you. Enough passive cooling for the whole journey including layovers, packs that will still read as frozen at a second screening, nothing pressed directly against the pens, and a thermometer so you know what actually happened rather than guessing.

Step 4: write down what happened. Date and time each pen leaves refrigeration, the highest temperature you saw, and which pens travelled warm. If a pen's history is unclear on arrival, that is a question for the pharmacy, not a judgement call at the injection site.

Step 5: build in the buffer. Extra doses beyond the exact count, because flights get cancelled, which is how this traveller ended up with a 42-hour itinerary in the first place.

A running log is genuinely the part people wish they had. If you already track symptoms, adding medication timing, temperature exposure and the dates around travel gives your team something concrete to read when you get back, and a summary to take to the appointment is one of the things Clairop is built to produce. Tracking does not change what your medication does; it changes how much of the story survives to the consultation.

A pre-flight checklist

Six to eight weeks out:

• Travel clinic appointment booked, vaccines discussed with the IBD team.
• Infusion or injection dates reviewed and moved if needed.
• Insurance bought with the condition declared.
• Destination rules checked for anything containing a controlled drug.

Two weeks out:

• Buffer supply dispensed, expiry dates checked.
• Storage section of your own leaflet read, allowance and ceiling temperature written down.
• Cool bag sourced and, if you are flying from a UK airport with ice packs rather than cooling gel packs, the airport contacted.
• Letter and prescription copies printed, generic drug names included.
• Written plan from the team for escalating symptoms abroad.

Day of travel:

• All medication in cabin bag, original cartons, leaflet included.
• Date written on the carton when anything leaves the fridge.
• Medication out of the bag and declared at screening where required.
• Buffer doses split across bags you are personally carrying, if you are travelling with someone.

Myths worth dropping

"Biologics are fine out of the fridge for 14 days." Only some are. Reading the US labels, the range is from no room-temperature allowance at all for subcutaneous risankizumab to 30 days for golimumab and ustekinumab syringes. Fourteen days is adalimumab's number.

"You need a doctor's letter to get medication through security." Not in the US, where TSA recommends clear labelling and requires you to declare oversized medically necessary liquids, and does not list a letter as a requirement. Not in the UK for a small pen either, since the proof requirement applies only to liquids in containers larger than 100 ml. Carry the letter for customs, the airline and resupply instead.

"Ice packs are always allowed in hand luggage." The GOV.UK table distinguishes cooling gel packs, allowed, from ice packs, listed as contact the airport. And travellers report packs that have thawed being refused at a second screening.

"The hold gets too hot." The direction of risk the evidence points to is cold, not heat. In home monitoring of people on biologic drugs for rheumatic disease, sub-zero exposure of more than two hours was twelve times more common than exceeding 25 degrees C (Vlieland 2016).

"A frozen pen is definitely ruined." Also not established. The freezing study found particle formation in 47.6% of stressed samples, but two of five analytical methods found no difference, and no study has tested whether a frozen-and-thawed pen works less well in a person. The label says do not freeze; treat a freezing event as a question for your pharmacy rather than either a disaster or a non-event.

"Flying causes flares." One small questionnaire study found an association, with flights and mountain journeys pooled into a single exposure, and it cannot attribute the effect to the flight (Vavricka 2014). A follow-up chamber study was announced; the abstract we could read does not report its results.

"Fixing your sleep prevents travel flares." Not shown. The circadian argument in IBD is explicitly framed as a hypothesis by the authors advancing it (Post 2025).

"You should pause your biologic before a trip to reduce infection risk." That is the opposite of what most specialists reported doing: two-thirds in a 23-country survey said they would continue all IBD treatments and cease none (Chan 2018). Any pause is your team's decision, and stopping a biologic has its own risks.

"IBD triples your clot risk, so everyone needs prophylaxis for a long flight." The three-fold figure is a relative risk from a consensus part-funded by AbbVie Canada, and that consensus does not recommend routine outpatient prophylaxis. Absolute risk in ambulant patients stayed below 5 per 1,000 person-years even during active disease (Chu 2018).

Anxiety about the journey is part of this, and it is reasonable

The threads are not only about logistics. One highly upvoted comment in the queue-skipping thread put the feeling plainly: people are not asking for special treatment out of a sense of superiority, they are frightened of an accident in a queue they cannot leave. That fear is doing real work in these decisions, and it deserves naming rather than a packing tip.

Two things help without pretending to fix it. The first is that most of the fear attaches to the parts you can actually control, which is why a written plan, a buffer supply and a known seat reduce it more than reassurance does. The second is that asking for help at an airport works more often than people expect: threads describe staff moving people forward without much explanation needed, and many airports run hidden-disability schemes such as a sunflower lanyard. None of that is a guaranteed entitlement; it varies by airport and by who you ask, and it is discretionary assistance rather than a right.

When to see a doctor promptly

Before you travel, contact your IBD team promptly rather than waiting for your next routine appointment if you have new or worsening blood in your stool, unexplained weight loss, fever, night-time symptoms that wake you, new severe abdominal pain, symptoms of anaemia such as breathlessness or unusual fatigue, or a clear increase in stool frequency and urgency over days. Flying during an active flare is something to decide with your team, not despite them: in one clinic survey, most people who had flared still travelled overseas during it (Greveson 2016), which is understandable and is also why the advice exists.

Seek urgent medical care, wherever you are, for cramping pain with vomiting and no passage of wind or stool, a rigid or very tender abdomen, heavy rectal bleeding, high fever with severe abdominal pain, calf pain or swelling or sudden breathlessness or chest pain after a long flight, or a stoma that stops working. Do not wait to get home.

And if diarrhoea starts abroad, ask about a stool test rather than assuming it is a flare, because roughly a quarter of symptomatic IBD patients tested during an exacerbation in one series had a detectable gut infection (Axelrad 2017).

The honest bottom line

Flying with Crohn's medication is a solvable logistics problem, and most of the difficulty comes from advice written as though all biologics behave the same way. They do not. The single most useful thing you can do is read the storage paragraph on your own leaflet, write down your allowance and your ceiling temperature, and plan the journey against those two numbers.

Beyond that: cabin bag rather than hold, because freezing is the error that actually happens and the hold is the part you cannot see. Original cartons and generic names, because customs and foreign pharmacies care more about documentation than the scanner does. A travel clinic appointment booked early, because the vaccine question is the one with a lead time. Insurance that names your condition, because a third of people with IBD do not have it. A written plan from your team for what to do if symptoms escalate, because that is the question you will not want to be asking from a hotel.

What the evidence does not support is fear. Flights are weakly and ambiguously associated with flares in one small study. Clot risk rises, from a small base, more so if you are flaring or recently post-surgical. Most specialists would keep your treatment running rather than pause it. The realistic worst case in the survey data is that about one person in thirteen sought medical advice or was hospitalised abroad, which is a reason to prepare rather than to stay home.